Marlin Health Inc. · CSE:MRLH
Marlin Health — FendX Technologies — Investor Presentation (January 2024)
20 slides from Marlin Health's investor presentation, January 2024
Slide 1: Making Lives Safer Through Nanotechnology
Making Lives Safer Through NANOTECHNOLOGY K E E P I N G S U R FA C E S C L E A N C O R P O R AT E D E C K CSE: FNDX | OTCQB: FDXTF | FSE: E8D JANUARY 2024
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface and coating
Slide 3: Developing novel protective nano-coatings to keep surfaces clean
Unique Disruptive Nanotechnology Potential to Access Multi-Million-Dollar Award-winning, patent pending nanotechnology Markets with instant repelling properties against Focus on protecting high-touch surfaces (i.e., bacteria, viruses, blood and liquids healthcare, transportation, entertainment & sch
Slide 4: Keeping Surfaces Clean Requires Innovative Solutions
Keeping Surfaces Clean Requires Innovative Solutions Problem Solution • High-touch surfaces and catheters are potential • FendX is developing nano-coating products to sources of contamination that can lead to protect high-touch surfaces and catheters from healthcare-associated infections contaminati
Slide 5: Product Pipeline
Product Pipeline Prototype Intermediate Real-World Commercial Development Scale-Up Beta-Testing Production Developing film and spray coatings to reduce the spread of bacteria and REPELWRAP film viruses on high-touch surfaces prone to contamination Spray Nano-Coating Prototype Intermediate Developing
Slide 6: Protecting High-Touch Surfaces Prone to Contamination
Protecting High-Touch Surfaces Prone to Coated with Nanotechnology Contamination How Our Nano-Coating Works • When a contaminated hand touches a nano-coated surface, Uncoated the contamination tends to stay on the hand and not transfer to the surface1,2,3 Sources: 1. https://pubs.acs.org/doi/10.1021
Slide 7: REPELWRAP Film
REPELWRAP Film Lead Product in Development to Protect High Touch Surfaces Prone to Contamination • Provides immediate, 24/7 protection for extended periods of time • Being developed for easy application to flat surfaces, handrails etc. • Effective repelling rates: • >99% reduction in adhesion of a C
Slide 8: REPELWRAP Film Composition in Scale-up Development
REPELWRAP Film Plasma Treatment Film Composition in Scale-up Development Nanoparticle & Fluoropolymer Deposition • Involves deposition of nanoparticles and fluoropolymers on plastic film and then thermally shrunk Thermal Shrinking • Creates an inert surface with unique repelling properties that prev
Slide 9: REPELWRAP Film Scale-Up and Pilot Manufacturing
REPELWRAP Film Currently in Scale-Up Development and Pilot Manufacturing Runs With Dunmore* • Production time streamlined • Achieved the expected repelling properties • In the process of optimizing formulation and manufacturing process • Anticipate introduction of a commercial product in 2H2024 * Du
Slide 10: REPELWRAP Spray
REPELWRAP Spray In Development to Protect High Touch Surfaces Prone to Contamination: • Expected to be easier to apply providing immediate and 24/7 protection for extended periods of time and expand applications • Both repels and kills: • >98% reduction in adhesion of MRSA and Covid- 19 like virus1
Slide 11: REPELWRAP Film and Spray Competitive Landscape
REPELWRAP Film and Spray Competitive Landscape Metal-Containing* REPELWRAP Liquid and Photo- Film1 Disinfectants Activated Films** Surface repels bacteria, viruses, +++ - - blood and liquids Instantly effective +++ +++ + 24/7 protection +++ - +++ Does not promote bacterial resistance +++ + + * Silve
Slide 12: Developing Nano-Coating for Catheters to Reduce Bacterial Infections and Blood Clot Formation
Developing Nano-Coating for Catheters to Reduce Bacterial Infections and Blood Clot Formation Findings from early-stage research of our Estimated annual infection cases and cost nanotechnology that is lubricant infused1: of common catheter complications in U.S. • Lubricant infused nano-surface prov
Slide 13: Building A Robust Patent Portfolio
Building A Robust Patent Portfolio Protecting Licensed Nanotechnology Used to Develop Film, Spray and Catheter Coatings Family 1 - Film Coating: • Canada Patent Application Number 3142127, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF • European Pa
Slide 14: Antimicrobial & Antiviral Nano-Coating Market Offers Significant Opportunity
Antimicrobial & Antiviral Nano-Coating Market Offers Significant Opportunity Global market estimated to reach US$1.3 billion in 20261 $1,400 $1.3B $1,200 $1,000 $800 $600 $400 $200 $0 2022 2023 2024 2025 2026 1. Future Markets Technology Report, Advanced Microbial Coatings, 2021 CSE: FNDX | OTCQB: F
Slide 15: Partnership Strategy with Manufacturers and Distributors
Partnership Strategy with Manufacturers and Distributors Manufacturers Sales Distributors Plan to establish partnerships to Plan to secure partnerships to sell manufacture REPELWRAPTM film and REPELWRAPTM film in Canada, U.S. and other products for distribution in other global markets Canada, U.S. a
Slide 16: Growth Strategy
Growth Strategy • Explore additional uses of nanotechnology • Assess licensing/acquisition opportunities to expand product pipeline and intellectual property portfolio • Initial REPELWRAP film product launch in Canada estimated 2H2024, with expansion into the U.S. and other markets CSE: FNDX | OTCQB
Slide 17: Proven Management Team
Proven Management Team Dr. Carolyn Myers MBA, PhD Andrea Mulder BPHE, MBA Rose Zanic CPA, CA President, CEO & Director COO CFO & Corporate Secretary • Principal of BioEnsemble LLC, assisting • Over 25 years of pharma/biotech • Over 25 years of capital markets and start-ups and small pharma companies
Slide 18: Board of Directors
Board of Directors Dr. Carolyn Myers MBA, PhD Stephen Randall CPA, CGA Pierre Soulard B.C.L., LLB, LLM President, CEO & Director Independent Board Member Independent Board Member & Audit Committee Chair • Principal of BioEnsemble LLC, • Former Chief Legal Officer of CoinSmart assisting start-ups and
Slide 19: Share Structure
Share Structure CSE: FNDX / AS OF DECEMBER 31, 2023 Common Stock1 53,284,893 Stock Options 2,741,667 • Efficient capital structure Warrants 15,612,520 • Over 46%1 of outstanding common shares subject to escrow/pooling Bonus Shares2 4,150,000 restrictions Fully-Diluted 75,789,080 1 24,725,401 shares
Slide 20: Thank You!
Thank You! Reach out to us with any questions. [email protected] / fendxtech.com CSE: FNDX | OTCQB: FDXTF | FSE:E8D JANUARY 2024 / 20
FendX Technologies — Investor Presentation (January 2024) on 6ix